| Previous Close | 146.81 |
| Open | 146.09 |
| Bid | 141.85 x 800 |
| Ask | 141.63 x 1000 |
| Day's Range | 138.46 - 147.32 |
| 52 Week Range | 19.31 - 189.26 |
| Volume | 2,744,727 |
| Avg. Volume | 19,090,858 |
| Market Cap | 55.654B |
| Beta (5Y Monthly) | 1.50 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.96 |
| Earnings Date | May 05, 2021 - May 10, 2021 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 168.85 |
- Editor's PickYahoo Finance
Doctor endorses J&J's COVID-19 shot, all 3 vaccines a 'path to ending the pandemic'
Public health experts have dismissed concerns about J&J' vaccine and stressed its importance.
- Editor's PickYahoo Finance
J&J single-dose vaccine is 'absolutely' a game changer: physician
Johnson & Johnson’s single-dose COVID-19 vaccine is ‘absolutely’ a game changer and will help ensure Americans are vaccinated at a faster pace, according to Dr. Sejal Hathi, physician and clinical fellow at Massachusetts General Hospital.
- Motley Fool
AstraZeneca Just Sold Its Moderna Stock: Should You?
Earlier this week, British newspaper The Times reported that AstraZeneca (NASDAQ: AZN) sold its entire stake in Moderna (NASDAQ: MRNA). Should other investors following AstraZeneca's lead and sell Moderna stock too? AstraZeneca first invested in Moderna in 2013, more than five years before the biotech conducted its initial public offering (IPO).
© 2021 Verizon Media. All rights reserved.
